<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <title>Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion</title>
</head>
<body>
  <a href="../../index.html">← Back to home</a>
  <h1>Zacks.com featured highlights include Halozyme Therapeutics, Leidos and TransUnion</h1>
  <ul>
<li>TransUnion's 2025 earnings are expected to rise 4.1% year over year.</li>
<li>Halozyme's 2025 earnings are expected to jump 46.1% year over year.</li>
<li>Leidos' 2025 earnings are projected to grow 9.2% on a year-over-year basis.</li>
<li>Its average gain has been a stellar +25% per year.</li>
<li>TRU, presently carrying a Zacks Rank #2, has witnessed a 5% upward revision in broker ratings over the past four weeks.</li>
<li>LDOS, carrying a Zacks Rank #2 at present, has witnessed a 5.6% upward revision in broker ratings over the past four weeks.</li>
<li>HALO, which currently sports a Zacks Rank #1, has witnessed a 9.1% upward revision in broker ratings over the past four weeks.</li>
</ul>
<p><a href="https://finance.yahoo.com/news/zacks-com-featured-highlights-halozyme-134200240.html">Source</a> · 2025-09-08T13:42:00+00:00</p>
</body>
</html>